Roivant Sciences Shares Rise Following Positive Late-Stage Trial Results for Lisraya
Roivant Sciences (ROIV) saw its stock price increase by nearly 7% in premarket trading on Wednesday. The surge follows positive news regarding late-stage clinical trial results for Lisraya (brepocitinib), an FDA-approved therapy developed by Roivant's subsidiary, Priovant Therapeutics. The successful trials specifically target non-infectious uveitis, a significant eye disorder. This development strengthens the market position of the brepocitinib treatment and provides positive clinical validation for Roivant's therapeutic pipeline.
Tickers: $ROIV
Topics: clinical trial success FDA approval stock price movement
Read the full article at Seeking Alpha
Part of the story Kimberly-Clark Shares Rise Amid Positive Developments (4 articles)